FASENRA Delays Time to First Flare in Hypereosinophilic Syndrome: NATRON Trial Results скачать в хорошем качестве

FASENRA Delays Time to First Flare in Hypereosinophilic Syndrome: NATRON Trial Results

The NATRON Phase III trial shows promising results for patients with Hypereosinophilic Syndrome (HES). AstraZeneca's FASENRA significantly delayed the time to first worsening or flare of HES, offering hope for those with this rare disease. The trial demonstrated a 65% reduction in the risk of HES worsening compared to placebo, and patients experienced improved fatigue symptom relief with a single monthly dose. HES is a group of rare disorders characterized by high levels of eosinophils, a type of white blood cell, leading to organ damage. Current treatments include glucocorticosteroids, chemotherapy, and monoclonal antibodies. The NATRON trial evaluated FASENRA's efficacy and safety in HES patients, and the positive results were presented at the ACAAI 2025 Annual Scientific Meeting. The trial's principal investigator, Dr. Princess U. Ogbogu, highlights the potential of FASENRA to significantly reduce flares and improve fatigue severity in HES patients. AstraZeneca's Executive Vice President, Sharon Barr, emphasizes FASENRA's ability to address eosinophilic inflammation in difficult-to-treat diseases like HES and eosinophilic granulomatosis with polyangiitis, in addition to severe eosinophilic asthma. The NATRON trial met all key secondary endpoints, showing fewer patients experiencing flares and a reduced annualized rate of HES flares with FASENRA treatment. The safety profile of FASENRA in the trial was consistent with its known profile. FASENRA is currently approved for severe eosinophilic asthma in many countries and for eosinophilic granulomatosis with polyangiitis in over 60 countries.